{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:02:49Z","timestamp":1789455769092,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,8]]},"DOI":"10.7759\/cureus.85564","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T18:13:42Z","timestamp":1749406422000},"source":"Crossref","is-referenced-by-count":3,"title":["Comparative Risk Assessment in Hypertensive Patients With Metabolic Syndrome by Exploring Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers"],"prefix":"10.7759","author":[{"given":"Muhammad Haris","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soobia","family":"Pathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashaf","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidra","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Ghafoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeeha","family":"Minhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-021-01615-y","article-title":"Metabolic syndrome and cognitive function","volume":"23","author":"Tahmi M","year":"2021","unstructured":"Tahmi M, Palta P, Luchsinger JA. Metabolic syndrome and cognitive function. Curr Cardiol Rep. 2021, 23:180. 10.1007\/s11886-021-01615-y","journal-title":"Curr Cardiol Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-025-04947-w","article-title":"Linking metabolic syndrome to neurodegeneration mechanisms and potential treatments [Online ahead of print]","author":"D\u017eidi\u0107-Krivi\u0107 A","year":"2025","unstructured":"D\u017eidi\u0107-Krivi\u0107 A, Fajki\u0107 A, Farhat EK, et al.. Linking metabolic syndrome to neurodegeneration mechanisms and potential treatments [Online ahead of print]. Mol Neurobiol. 2025, 10.1007\/s12035-025-04947-w","journal-title":"Mol Neurobiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2020-000813","article-title":"Metabolic syndrome, intracranial arterial stenosis and cerebral small vessel disease in community-dwelling populations","volume":"6","author":"Shu MJ","year":"2021","unstructured":"Shu MJ, Zhai FF, Zhang DD, et al.. Metabolic syndrome, intracranial arterial stenosis and cerebral small vessel disease in community-dwelling populations. Stroke Vasc Neurol. 2021, 6:589-94. 10.1136\/svn-2020-000813","journal-title":"Stroke Vasc Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00640-5","article-title":"Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer's disease","volume":"18","author":"Inoue Y","year":"2023","unstructured":"Inoue Y, Shue F, Bu G, Kanekiyo T. Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer's disease. Mol Neurodegener. 2023, 18:46. 10.1186\/s13024-023-00640-5","journal-title":"Mol Neurodegener"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcsop.2023.100315","article-title":"Prescribing patterns of antihypertensive medications: a systematic review of literature between 2010 and 2020","volume":"11","author":"Abdelkader NN","year":"2023","unstructured":"Abdelkader NN, Awaisu A, Elewa H, El Hajj MS. Prescribing patterns of antihypertensive medications: a systematic review of literature between 2010 and 2020. Explor Res Clin Soc Pharm. 2023, 11:100315. 10.1016\/j.rcsop.2023.100315","journal-title":"Explor Res Clin Soc Pharm"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2022.10.152","article-title":"The utilization, expenditure, and price of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the US Medicaid programs: trends over a 31 year period","volume":"370","author":"Almadfaa RO","year":"2023","unstructured":"Almadfaa RO, Wigle PR, Hincapie AL, Guo JJ. The utilization, expenditure, and price of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the US Medicaid programs: trends over a 31 year period. Int J Cardiol. 2023, 370:412-8. 10.1016\/j.ijcard.2022.10.152","journal-title":"Int J Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-023-01266-0","article-title":"Angiotensin receptor blockers and cognition: a scoping review","volume":"26","author":"Zhou Z","year":"2024","unstructured":"Zhou Z, Orchard SG, Nelson MR, Fravel MA, Ernst ME. Angiotensin receptor blockers and cognition: a scoping review. Curr Hypertens Rep. 2024, 26:1-19. 10.1007\/s11906-023-01266-0","journal-title":"Curr Hypertens Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15806","article-title":"Angiotensin-converting enzymes as druggable features of psychiatric and neurodegenerative disorders","volume":"166","author":"Santiago TC","year":"2023","unstructured":"Santiago TC, Parra L, Nani JV, Fidalgo TM, Bradshaw NJ, Hayashi MA. Angiotensin-converting enzymes as druggable features of psychiatric and neurodegenerative disorders. J Neurochem. 2023, 166:138-55. 10.1111\/jnc.15806","journal-title":"J Neurochem"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-1566-9_4","article-title":"Assessing heterogeneity in random-effects meta-analysis","volume":"2345","author":"Langan D","year":"2022","unstructured":"Langan D. Assessing heterogeneity in random-effects meta-analysis. Methods Mol Biol. 2022, 2345:67-89. 10.1007\/978-1-0716-1566-9_4","journal-title":"Methods Mol Biol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.20680","article-title":"Risk of mild cognitive impairment or probable dementia in new users of angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors: a secondary analysis of data from the Systolic Blood Pressure Intervention Trial (SPRINT)","volume":"5","author":"Cohen JB","year":"2022","unstructured":"Cohen JB, Marcum ZA, Zhang C, et al.. Risk of mild cognitive impairment or probable dementia in new users of angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors: a secondary analysis of data from the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA Netw Open. 2022, 5:e2220680. 10.1001\/jamanetworkopen.2022.20680","journal-title":"JAMA Netw Open"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.19378","article-title":"Angiotensin receptor blockers are associated with lower risk of progression from mild cognitive impairment to dementia in hypertensive patients","volume":"79","author":"Deng Z","year":"2022","unstructured":"Deng Z, Jiang J, Wang J, et al.. Angiotensin receptor blockers are associated with lower risk of progression from mild cognitive impairment to dementia in hypertensive patients. Hypertension. 2022, 79:2159-69. 10.1161\/HYPERTENSIONAHA.122.19378","journal-title":"Hypertension"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281460","article-title":"Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction","volume":"18","author":"Lee JG","year":"2023","unstructured":"Lee JG, Joo SJ, Kim SY, et al.. Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction. PLoS One. 2023, 18:e0281460. 10.1371\/journal.pone.0281460","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2020.12.011","article-title":"Associations between brain amyloid accumulation and the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers","volume":"100","author":"Ouk M","year":"2021","unstructured":"Ouk M, Wu CY, Rabin JS, et al.. Associations between brain amyloid accumulation and the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. Neurobiol Aging. 2021, 100:22-31. 10.1016\/j.neurobiolaging.2020.12.011","journal-title":"Neurobiol Aging"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glaf028","article-title":"Effect of initiation and continuous adherence to ARBs vs. ACEIs on risk of adjudicated mild cognitive impairment or dementia","volume":"2025","author":"Derington CG","year":"2025","unstructured":"Derington CG, Berchie RO, Scharfstein DO, et al.. Effect of initiation and continuous adherence to ARBs vs. ACEIs on risk of adjudicated mild cognitive impairment or dementia. J Gerontol A Biol Sci Med Sci. 2025, 2025:glaf028. 10.1093\/gerona\/glaf028","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010996","article-title":"Association between antihypertensive medication classes and dementia: post hoc analysis of the PreDIVA randomized clinical trial","volume":"96","author":"Van Dalen JW","year":"2021","unstructured":"Van Dalen JW, Marcum ZA, Gray SL, et al.. Association between antihypertensive medication classes and dementia: post hoc analysis of the PreDIVA randomized clinical trial. Neurology. 2021, 96:67-80. 10.1212\/WNL.0000000000010996","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105378","article-title":"Association between risk of Alzheimer's disease and related dementias and angiotensin receptor \u2161 blockers treatment for individuals with hypertension in high-volume claims data","volume":"109","author":"Lundin SK","year":"2024","unstructured":"Lundin SK, Hu X, Feng J, et al.. Association between risk of Alzheimer's disease and related dementias and angiotensin receptor \u2161 blockers treatment for individuals with hypertension in high-volume claims data. EBioMedicine. 2024, 109:105378. 10.1016\/j.ebiom.2024.105378","journal-title":"EBioMedicine"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00778-8","article-title":"The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer's disease: the importance of blood-brain barrier penetration and APOE \u03b54 carrier status","volume":"13","author":"Ouk M","year":"2021","unstructured":"Ouk M, Wu CY, Rabin JS, et al.. The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer's disease: the importance of blood-brain barrier penetration and APOE \u03b54 carrier status. Alzheimers Res Ther. 2021, 13:43. 10.1186\/s13195-021-00778-8","journal-title":"Alzheimers Res Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.16667","article-title":"Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study","volume":"78","author":"Chen R","year":"2021","unstructured":"Chen R, Suchard MA, Krumholz HM, et al.. Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension. 2021, 78:591-603. 10.1161\/HYPERTENSIONAHA.120.16667","journal-title":"Hypertension"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-180943","article-title":"Observational study of brain atrophy and cognitive decline comparing a sample of community-dwelling people taking angiotensin converting enzyme inhibitors and angiotensin receptor blockers over time","volume":"68","author":"Moran C","year":"2019","unstructured":"Moran C, Xie K, Poh S, et al.. Observational study of brain atrophy and cognitive decline comparing a sample of community-dwelling people taking angiotensin converting enzyme inhibitors and angiotensin receptor blockers over time. J Alzheimers Dis. 2019, 68:1479-88. 10.3233\/JAD-180943","journal-title":"J Alzheimers Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.17595","article-title":"Blood-brain barrier crossing renin-angiotensin system drugs: considerations for dementia and cognitive decline","volume":"78","author":"Glodzik L","year":"2021","unstructured":"Glodzik L, Santisteban MM. Blood-brain barrier crossing renin-angiotensin system drugs: considerations for dementia and cognitive decline. Hypertension. 2021, 78:644-6. 10.1161\/HYPERTENSIONAHA.121.17595","journal-title":"Hypertension"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15092290","article-title":"Therapeutic implications of renin-angiotensin system modulators in Alzheimer's dementia","volume":"15","author":"Ababei DC","year":"2023","unstructured":"Ababei DC, Bild V, Macadan I, et al.. Therapeutic implications of renin-angiotensin system modulators in Alzheimer's dementia. Pharmaceutics. 2023, 15:2290. 10.3390\/pharmaceutics15092290","journal-title":"Pharmaceutics"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac076","article-title":"Blood-brain barrier permeable \u03b2-blockers linked to lower risk of Alzheimer's disease in hypertension","volume":"146","author":"Beaman EE","year":"2023","unstructured":"Beaman EE, Bonde AN, Larsen SM, et al.. Blood-brain barrier permeable \u03b2-blockers linked to lower risk of Alzheimer's disease in hypertension. Brain. 2023, 146:1141-51. 10.1093\/brain\/awac076","journal-title":"Brain"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14102123","article-title":"Angiotensin II receptor blockers in the management of hypertension in preventing cognitive impairment and dementia-a systematic review","volume":"14","author":"D'Silva E","year":"2022","unstructured":"D'Silva E, Meor Azlan NF, Zhang J. Angiotensin II receptor blockers in the management of hypertension in preventing cognitive impairment and dementia-a systematic review. Pharmaceutics. 2022, 14:2123. 10.3390\/pharmaceutics14102123","journal-title":"Pharmaceutics"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1017\/neu.2023.38","article-title":"Pharmacogenetics of angiotensin modulators according to APOE-\u03f54 alleles and the ACE insertion\/deletion polymorphism in Alzheimer's disease","volume":"35","author":"Oliveira FF","year":"2023","unstructured":"Oliveira FF, Almeida SS, Chen ES, Smith MC, Bertolucci PH. Pharmacogenetics of angiotensin modulators according to APOE-\u03f54 alleles and the ACE insertion\/deletion polymorphism in Alzheimer's disease. Acta Neuropsychiatr. 2023, 35:346-61. 10.1017\/neu.2023.38","journal-title":"Acta Neuropsychiatr"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpu197","article-title":"Neuroprotective effects of angiotensin receptor blockers","volume":"28","author":"Villapol S","year":"2015","unstructured":"Villapol S, Saavedra JM. Neuroprotective effects of angiotensin receptor blockers. Am J Hypertens. 2015, 28:289-99. 10.1093\/ajh\/hpu197","journal-title":"Am J Hypertens"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15030924","article-title":"Angiotensin II receptor blockers reduce tau\/A\u00df42 ratio: a cerebrospinal fluid biomarkers' case-control study","volume":"15","author":"Garc\u00eda-Lluch G","year":"2023","unstructured":"Garc\u00eda-Lluch G, Pe\u00f1a-Bautista C, Royo LM, Baquero M, Ca\u00f1ada-Mart\u00ednez AJ, Ch\u00e1fer-Peric\u00e1s C. Angiotensin II receptor blockers reduce tau\/A\u00df42 ratio: a cerebrospinal fluid biomarkers' case-control study. Pharmaceutics. 2023, 15:924. 10.3390\/pharmaceutics15030924","journal-title":"Pharmaceutics"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.18255","article-title":"Effect of antihypertensive treatment on cerebral blood flow in older adults: a systematic review and meta-analysis","volume":"79","author":"van Rijssel AE","year":"2022","unstructured":"van Rijssel AE, Stins BC, Beishon LC, Sanders ML, Quinn TJ, Claassen JA, de Heus RA. Effect of antihypertensive treatment on cerebral blood flow in older adults: a systematic review and meta-analysis. Hypertension. 2022, 79:1067-78. 10.1161\/HYPERTENSIONAHA.121.18255","journal-title":"Hypertension"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1080\/13546805.2021.1931085","article-title":"Behavioural effects of the ACE insertion\/deletion polymorphism in Alzheimer's disease depend upon stratification according to APOE-\u03f54 carrier status","volume":"26","author":"Oliveira FF","year":"2021","unstructured":"Oliveira FF, de Almeida SS, Smith MC, Bertolucci PH. Behavioural effects of the ACE insertion\/deletion polymorphism in Alzheimer's disease depend upon stratification according to APOE-\u03f54 carrier status. Cogn Neuropsychiatry. 2021, 26:293-305. 10.1080\/13546805.2021.1931085","journal-title":"Cogn Neuropsychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/375526-comparative-risk-assessment-in-hypertensive-patients-with-metabolic-syndrome-by-exploring-angiotensin-converting-enzyme-inhibitors-and-angiotensin-ii-receptor-blockers","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T18:13:43Z","timestamp":1749406423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/375526-comparative-risk-assessment-in-hypertensive-patients-with-metabolic-syndrome-by-exploring-angiotensin-converting-enzyme-inhibitors-and-angiotensin-ii-receptor-blockers"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,8]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.85564","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,8]]}}}